Published Online: 2025 October 25 **Editorial**

Botulinum Toxin in Focus: Applications, Challenges, and Future Directions

Soheila Aminzadeh [1, 2], Maryam Shirani [1, *]

[1] Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
[2] Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

[*] ***Corresponding Author:*** Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: mshirani86@yahoo.com

Received: 13 September, 2025; **Revised:** 13 October, 2025; **Accepted:** 19 October, 2025

Keywords: Botulinum Toxin, Challenges, Future Direction

Dear Editor,

Few substances embody medical duality as starkly as botulinum toxin (BoNT), a molecule capable of killing with a single nanogram, yet trusted by millions to smooth wrinkles, silence migraines, and restore function. Once feared as a bioweapon, BoNT now stands as a pillar of modern therapeutics. However, with great power comes great responsibility and risk. This editorial argues that while BoNT's clinical expansion is remarkable, its dual-use nature demands stricter oversight, smarter delivery systems, and global coordination to prevent misuse without stifling innovation. *Clostridium botulinum* primarily produces BoNTs; this anaerobic, spore-forming, gram-positive bacterium, along with related species including *C. butyricum*, *C. baratii*, and *C. argentinensis*, synthesizes various toxin forms (1, 2). The BoNT is one of the most poisonous biological substances known, which appears in the environment, frequently in the form of spores, and causes several clinical syndromes known as botulism, characterized by paralysis, respiratory failure, and, if untreated, death (3, 4). This syndrome occurs after eating contaminated food, wound infection, or colonization of the infant's gut (5). The BoNT molecular mechanism of action involves the intracellular blocking of the acetylcholine release at nerve terminals, leading to disruption of the neurotransmission and progressive paralysis (6). Researchers estimate that the human median lethal dose (LD50) for botulism is 1 to 3 nanograms per kilogram of body mass, making it one of the most lethal substances worldwide (7). Because of its high toxicity, lethality, and possible application as a biological weapon, the Centers for Disease Control and Prevention (CDC) classifies BoNT as a category A agent (8).

Despite its toxicity, clinicians and researchers increasingly use BoNTs in modern medicine across various fields, including urology, dermatology, cosmetic medicine, neurology, pain management, oncology, and psychiatry, with a broader range of clinical applications than any other available pharmacological drugs (9). Medically controlled doses of BoNT formulations treat various disorders, including cervical dystonia, blepharospasm, hemifacial spasm, focal spasticity, chronic migraine, overactive bladder, excessive sweating, and cosmetic issues such as vertical and horizontal frown lines and crow's feet. Researchers also investigate its potential for painful keloids, diabetic neuropathic pain, trigeminal neuralgia, scarring, cancer, and depression (10-12). The therapeutic mechanism of BoNT is based on the same neuromuscular blocking effect that makes the toxin extremely dangerous; however, under close medical supervision, clinicians have transformed BoNT from a lethal neurotoxin into a highly therapeutic agent with wide-ranging clinical applications (13).

In therapeutic doses, clinicians consider BoNT generally safe with relatively few self-limited negative effects, including muscle weakness, extreme tiredness, dizziness, oral dryness, flu-like illness, and a skin rash

How to Cite: Aminzadeh S, Shirani M. Botulinum Toxin in Focus: Applications, Challenges, and Future Directions. Jundishapur J Nat Pharm Prod. 2026; 21 (1): e166127. https://doi.org/10.5812/jjnpp-166127.

(14, 15). Serious complications are rare but possible, including neurological problems, spread to non-target muscles, anaphylactic reactions, and other adverse events; therefore, prescribers must recognize its potential risks (16, 17). Furthermore, the development of neutralizing antibodies (NAbs), effective antitoxins, new delivery systems (such as nanoparticles), and vaccines [including the tetravalent botulinum vaccine (TBV)] plays a critical role in reducing the potential risks associated with clinical use and accidental or intentional exposure (18-22).

Future research on BoNT should prioritize innovations that enhance its therapeutic precision, safety, and duration of action. Advances in biotechnology — such as nanocarriers, targeted delivery systems, and engineered BoNT variants — offer promising strategies to optimize its medical potential while minimizing risks of misuse. To harness BoNT's full potential while minimizing risk, we urge: (1) Standardized global surveillance for antibody development, (2) investment in targeted delivery platforms to reduce off-target effects, and (3) the establishment of ethical frameworks for emerging psychiatric and oncological applications. Such coordinated action will ensure BoNT's continued evolution as both a powerful and responsibly managed therapeutic tool for future medicine.

Footnotes

Authors' Contribution: The manuscript was written by S. A. and M. Sh., with revisions made by M. Sh. Both authors reviewed and approved the final version.

Conflict of Interests Statement: The corresponding author is one of the editorial board members.

Funding/Support: The present sturdy received no funding/support.

References

1. Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. *Toxins*. 2021;**13**(1):58. [PubMed ID: 33466571]. [PubMed Central ID: PMC7828686]. https://doi.org/10.3390/toxins13010058.
2. Kumar R, Singh BR. Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action. *Int J Mol Sci*. 2025;**26**(2):777. [PubMed ID: 39859491]. [PubMed Central ID: PMC11766063]. https://doi.org/10.3390/ijms26020777.
3. Nigam PK, Nigam A. Botulinum toxin. *Indian J Dermatol*. 2010;**55**(1):8-14. [PubMed ID: 20418969]. [PubMed Central ID: PMC2856357]. https://doi.org/10.4103/0019-5154.60343.
4. Skryabina AA, Golenok ES, Sobkh MM, Nikiforov VV. Structure and mechanism of action of botulinum and tetanus neurotoxins: A review. *Epidemiol Infect Dis*. 2023;**28**(2):118-27. https://doi.org/10.17816/eid321328.
5. Jeffery I, Nguyen A, Karim S. *Botulism*. Treasure Island (FL): StatPearls; 2024.
6. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. *Eur Neurol*. 2005;**53**(1):3-9. [PubMed ID: 15650306]. https://doi.org/10.1159/000083259.
7. Horowitz BZ. Botulinum toxin. *Crit Care Clin*. 2005;**21**(4):825-39. viii. [PubMed ID: 16168317]. https://doi.org/10.1016/j.ccc.2005.06.008.
8. Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. *Indian J Med Res*. 2010;**132**(5):489-503. [PubMed ID: 21149997]. [PubMed Central ID: PMC3028942].
9. Kumar R. Therapeutic use of botulinum toxin in pain treatment. *Neuronal Signal*. 2018;**2**(3):NS20180058. [PubMed ID: 32714587]. [PubMed Central ID: PMC7373233]. https://doi.org/10.1042/NS20180058.
10. Pickett A, Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. *Toxins*. 2011;**3**(1):63-81. [PubMed ID: 22069690]. [PubMed Central ID: PMC3210455]. https://doi.org/10.3390/toxins3010063.
11. Watkins JC, Middelkoop J, Taylor K, Filipova D, Hartung T, Visseren-Hamakers I, et al. Botulinum neurotoxin: Tracking the transition from lethal dose to in vitro models. *NAM J*. 2025;**1**. https://doi.org/10.1016/j.namjnl.2025.100040.
12. Hemmati AA, Alanchari N, Armanpour M, Aminzadeh S. Migraine relief through botulinum toxin therapy: Exploring the science behind a modern treatment. *Toxicon*. 2025;**265**:108488. [PubMed ID: 40639491]. https://doi.org/10.1016/j.toxicon.2025.108488.
13. Ayoub N. Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights. *J Clin Med*. 2025;**14**(6). [PubMed ID: 40142828]. [PubMed Central ID: PMC11943293]. https://doi.org/10.3390/jcm14062021.
14. Witmanowski H, Blochowiak K. The whole truth about botulinum toxin - a review. *Postepy Dermatol Alergol*. 2020;**37**(6):853-61. [PubMed ID: 33603602]. [PubMed Central ID: PMC7874868]. https://doi.org/10.5114/ada.2019.82795.
15. Klein AW. Complications and adverse reactions with the use of botulinum toxin. *Dis Mon*. 2002;**48**(5):336-56. [PubMed ID: 12195264]. https://doi.org/10.1053/mda.2001.25964.
16. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. *Mov Disord*. 2013;**28**(13):1775-83. [PubMed ID: 23868503]. https://doi.org/10.1002/mds.25582.
17. Liguori V, Anatriello A, Cantone A, Nicoletti MM, Argenziano G, Scavone C, et al. The Use of Botulinum Toxin Type A and the Occurrence of Anaphylaxis: A Descriptive Analysis of Data from the European Spontaneous Reporting System. *Aesthetic Plast Surg*. 2025;**49**(7):2032-9. [PubMed ID: 39638899]. https://doi.org/10.1007/s00266-024-04564-3.
18. Jankovic J, Carruthers J, Naumann M, Ogilvie P, Boodhoo T, Attar M, et al. Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX((R))) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. *Toxins*. 2023;**15**(5):342. [PubMed

ID: 37235376]. [PubMed Central ID: PMC10224273]. https://doi.org/10.3390/toxins15050342.

19. Ni SA, Brady MF. *Botulism antitoxin*. Treasure Island (FL): StatPearls Publishing; 2023.
20. Sergeevichev D, Fomenko V, Strelnikov A, Dokuchaeva A, Vasilieva M, Chepeleva E, et al. Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models. *Mar Drugs*. 2020;**18**(8):410. [PubMed ID: 32748868]. [PubMed Central ID: PMC7460516]. https://doi.org/10.3390/md18080410.
21. Shi DY, Liu FJ, Li ZY, Mao YY, Lu JS, Wang R, et al. Development and evaluation of a tetravalent botulinum vaccine. *Hum Vaccin Immunother*. 2022;**18**(5):2048621. [PubMed ID: 35435814]. [PubMed Central ID: PMC9196761]. https://doi.org/10.1080/21645515.2022.2048621.
22. Ebrahimi F, Abedi MR. Expression, Purification, and Verification of Recombinant Botulinum Neurotoxin Type A Binding Domain: A Comparison Between X33 and PichiaPink Strains of Pichia pastoris. *Jundishapur J Nat Pharm Prod*. 2020;**15**(3). https://doi.org/10.5812/jjnpp.80447.